Compare Twist Bioscience Corp (TWST) vs Xylem, Inc. (XYL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Twist Bioscience Corp vs Xylem, Inc. — how do they compare? Twist Bioscience Corp trades at $123.3 (market cap $7.72B), while Xylem, Inc. trades at $120.83 (market cap $28.76B). The key difference: Xylem, Inc. is far larger — about 3.7× Twist Bioscience Corp's market cap, and Xylem, Inc. pays a 1.4% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals.
| TWST | XYL | |
|---|---|---|
Market Cap | $7.72B | $28.76B |
Sector | Health | Industrials |
52-Week High | $124.88 | $152.95 |
52-Week Low | $24.16 | $106.34 |
Enterprise Value | $7.65B | $30.54B |
Dividend Yield | — | 1.4% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TWST is trading at $124.88, up 7.96% in the last 24 hours, near its pivot point of $121 with resistance at $129. The stock shows strong technical momentum with bullish moving averages, though RSI levels indicate overbought conditions. Revenue growth is robust, with fiscal 2026 Q3 revenue up 23% year-over-year to $118.4 million, but the company remains unprofitable with a net income margin of -31.66% and negative cash flow from operations. Recent news highlights an upsized $300 million public offering and expansion in AI-driven drug discovery.
The outlook for TWST is mixed; bullish analyst sentiment and AI growth potential are offset by persistent losses and high valuation multiples. Investment opportunity lies in sustained revenue expansion and path to profitability, but risks include cash burn, competitive pressures, and execution challenges in scaling operations. The stock's current price exceeds the consensus target of $106.14, suggesting limited near-term upside based on fundamentals.
Xylem (XYL) trades at $121.19, up 0.72% today, with a bullish technical trend and strong fundamental performance. The company reported Q2 2026 EPS of $1.46, beating estimates, and raised full-year profit guidance. Revenue growth is steady, with a net income margin of 11.15% in 2025. Recent acquisitions, like Cornell Pump and Roper Pump, aim to strengthen its industrial water technology presence. The stock shows bullish moving averages but a neutral RSI, with key resistance at $123.
Outlook remains positive due to earnings beats, margin expansion, and strategic acquisitions. Risks include execution of integration and macroeconomic pressures. Analyst consensus is a buy with a $150.43 price target, implying significant upside. Institutional activity is mixed, with some funds increasing stakes while others reduced holdings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →About Xylem, Inc.
Xylem is a global leader in water technology and offers a wide range of solutions, including the transport, treatment, testing, and efficient use of water for customers in the utility, industrial, commercial, and residential sectors. Xylem was spun off from ITT in 2011. Based in Rye Brook, New York, Xylem has a presence in over 150 countries and employs 16,200. The company generated $6.2 billion in revenue and $611 million in adjusted operating income in 2021.
Read more on XYL →
